However, based on our results of inapparent PI3K/AKT signaling with no superior effectivity of dual PI3K/mTOR inhibition, we focused our further investigations on principle effects and the impact of mTOR inhibition including its pre-clinical effectivity in TTLshort/high-risk ALL per se, using rapamycin as a prototypic mTOR inhibitor. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.